3-[2-[[(1,1-二甲基乙基)二甲基甲硅烷基]氧基]乙基]苯甲醛 | 874899-89-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-[2-[[(1,1-二甲基乙基)二甲基甲硅烷基]氧基]乙基]苯甲醛
• 英文名称: 3-(2-(tert-butyldimethylsilyloxy)ethyl)benzaldehyde
• 英文别名: 3-(2-{[Tert-butyl(dimethyl)silyl]oxy}ethyl)benzaldehyde；3-[2-[tert-butyl(dimethyl)silyl]oxyethyl]benzaldehyde
• CAS: 874899-89-5
• 化学式: C₁₅H₂₄O₂Si
• 分子量: 264.44
• InChiKey: FINXEMRTHMEPCJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.06
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-[2-[[(1,1-二甲基乙基)二甲基甲硅烷基]氧基]乙基]苯甲醛 在 四氢吡咯 、 吡啶 、 ammonium cerium (IV) nitrate 、 sodium sulfate 、 三乙胺 作用下， 以 四氢呋喃 、 aq. phosphate buffer 、 乙醚 、 二氯甲烷 、 水 为溶剂， 反应 24.41h， 生成
  参考文献：
  名称：

  A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility

  摘要：

  A dual-purpose strategy aimed at enhancing the binding affinity for microtubules and improving the water solubility of docetaxel led to the design and synthesis of a series of C-2- and C-3'-modified analogues. Both aims were realized when the C-3' phenyl group present in docetaxel was replaced with a propargyl alcohol. The resulting compound, 3f, was able to overcome drug resistance in cultured P-gp-overexpressing tumor cells and showed greater activity than docetaxel against drug-resistant A2780/AD ovarian cancer xenografts in mice. In addition, the considerably lower hydrophobicity of 3f relative to both docetaxel and paclitaxel led to better aqueous solubility. A molecular model of tubulin-bound 3f revealed novel hydrogen-bonding interactions between the propargyl alcohol and the polar environment provided by the side chains of Ser236, Glu27, and Arg320.

  DOI：

  10.1021/acs.jnatprod.7b00857
• 作为产物：
  描述：

  3-溴苯乙醇 在 咪唑 、 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 4.33h， 生成 3-[2-[[(1,1-二甲基乙基)二甲基甲硅烷基]氧基]乙基]苯甲醛
  参考文献：
  名称：

  [EN] IMMUNOPROTEASOME INHIBITORS
  [FR] INHIBITEURS D'IMMUNOPROTÉASOME

  摘要：

  本文提供了化合物，如式（I）的化合物，或其药用可接受盐，这些化合物是免疫蛋白酶体（如LMP2和LMP7）抑制剂。本文描述的化合物可用于治疗通过抑制免疫蛋白酶体可治疗的疾病。本文还提供了含有这些化合物的药物组合物和制备这些化合物的方法。

  公开号：

  WO2019099576A1

文献信息

• [EN] IMMUNOPROTEASOME INHIBITORS<br/>[FR] INHIBITEURS D'IMMUNOPROTÉASOME
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2019099576A1

  公开（公告）日：2019-05-23

  Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本文提供了化合物，如式（I）的化合物，或其药用可接受盐，这些化合物是免疫蛋白酶体（如LMP2和LMP7）抑制剂。本文描述的化合物可用于治疗通过抑制免疫蛋白酶体可治疗的疾病。本文还提供了含有这些化合物的药物组合物和制备这些化合物的方法。
• Thiazole Derivatives Having Vap-1 Inhibitory Activity
  申请人：Inoue Takayuki

  公开号：US20070254931A1

  公开（公告）日：2007-11-01

  A compound of the formula (I), (II), (III) or (IV): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.

  公式（I），（II），（III）或（IV）的化合物：其中每个符号如规范中所定义，或其药学上可接受的盐，可用作血管黏附蛋白-1（VAP-1）抑制剂，制药组合物，预防或治疗VAP-1相关疾病，特别是黄斑水肿的方法，该方法包括向受试者投予化合物或其药学上可接受的盐的有效量等。
• [EN] THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY<br/>[FR] DERIVES DE THIAZOLE PRESENTANT UNE ACTIVITE D'INHIBITION DE LA VAP-1
  申请人：ASTELLAS PHARMA INC

  公开号：WO2006011631A3

  公开（公告）日：2006-04-20
• A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility
  作者：Yun-Tao Ma、Yanting Yang、Pei Cai、De-Yang Sun、Pedro A. Sánchez-Murcia、Xiao-Ying Zhang、Wen-Qiang Jia、Lei Lei、Mengqi Guo、Federico Gago、Hongbo Wang、Wei-Shuo Fang

  DOI：10.1021/acs.jnatprod.7b00857

  日期：2018.3.23

  A dual-purpose strategy aimed at enhancing the binding affinity for microtubules and improving the water solubility of docetaxel led to the design and synthesis of a series of C-2- and C-3'-modified analogues. Both aims were realized when the C-3' phenyl group present in docetaxel was replaced with a propargyl alcohol. The resulting compound, 3f, was able to overcome drug resistance in cultured P-gp-overexpressing tumor cells and showed greater activity than docetaxel against drug-resistant A2780/AD ovarian cancer xenografts in mice. In addition, the considerably lower hydrophobicity of 3f relative to both docetaxel and paclitaxel led to better aqueous solubility. A molecular model of tubulin-bound 3f revealed novel hydrogen-bonding interactions between the propargyl alcohol and the polar environment provided by the side chains of Ser236, Glu27, and Arg320.